首页> 美国卫生研究院文献>The Journal of Clinical Investigation >The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma).
【2h】

The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma).

机译:HLA-DR和DQ基因控制系统性硬化症(硬皮病)中对DNA拓扑异构酶I的自身免疫反应。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

HLA class II alleles were determined using the PCR-RFLP method in Japanese systemic sclerosis (scleroderma) patients with (n = 28) or without (n = 34) anti-topoisomerase I antibodies (anti-topo I). Either the DQB1*0601 or *0301 allele was recognized in all anti-topo I positive patients, compared with 44% of anti-topo I negative patients (P < 0.00001, relative risk [RR] > 41) or 58% of Japanese healthy control subjects (P < 0.00001, RR > 24). Tyrosine at position 26 in the second hypervariable region in the beta 1 domain of the DQB1 gene is common to these two alleles and is not present in any other known DQB1 alleles. We also examined immunoreactivities of anti-topo I positive sera to four different autoantigenic B cell epitopes of topo I molecule that were expressed as recombinant fusion proteins. One major B cell epitope, located within the region corresponding to amino acid residues 74-248, was perfectly associated with the amino acid sequence FLEDR at positions 67-71 in the beta 1 domain of the DRB gene. Two other epitopes, corresponding to 316-441 or 658-700, were associated with the serologically defined HLA-DR52 antigen. Patients with both FLEDR and DR52 demonstrated higher anti-topo I antibody titers. These results suggest that the HLA-DR and DQ genes together control the autoimmune response to topo I in systemic sclerosis.
机译:使用PCR-RFLP方法在日本全身性硬化症(硬皮病)患者中,使用(n = 28)或不使用(n = 34)抗拓扑异构酶I抗体(anti-topo I)来确定HLA II类等位基因。在所有抗拓扑I阳性患者中均识别出DQB1 * 0601或* 0301等位基因,相比之下,抗拓扑I阴性患者中有44%(P <0.00001,相对风险[RR]> 41)或日本健康人群中的58%对照受试者(P <0.00001,RR> 24)。 DQB1基因的beta 1域中第二个高变区中第26位的酪氨酸是这两个等位基因共有的,在任何其他已知的DQB1等位基因中均不存在。我们还检查了抗拓扑I阳性血清对以重组融合蛋白表达的topo I分子的四种不同自身抗原B细胞表位的免疫反应性。位于对应于氨基酸残基74-248的区域内的一个主要B细胞表位与DRB基因的β1结构域中67-71位的氨基酸序列FLEDR完美结合。对应于316-441或658-700的另外两个表位与血清学定义的HLA-DR52抗原相关。同时患有FLEDR和DR52的患者表现出较高的抗拓扑I抗体效价。这些结果表明,HLA-DR和DQ基因共同控制系统性硬化中对topo I的自身免疫反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号